ELUT Elutia Forecast, Technical & Fundamental Analysis
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices... Show more
ELUT is expected to report earnings to fall 11.76% to -15 cents per share on August 12
Q2'26
Est.
$-0.15
Q1'26
Missed
by $0.02
Q4'25
Beat
by $1.60
Q3'25
Missed
by $0.04
Q2'25
Missed
by $0.07
The last earnings report on May 14 showed earnings per share of -17 cents, missing the estimate of -15 cents. With 44.37K shares outstanding, the current market capitalization sits at 44.21M.
A.I.dvisor tells us that ELUT and XAIR have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ELUT and XAIR's prices will move in lockstep.
ELUT sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for ELUT moved above the 200-day moving average on May 20, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 57 cases where ELUT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 17, 2026. You may want to consider a long position or call options on ELUT as a result. In of 109 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ELUT just turned positive on June 22, 2026. Looking at past instances where ELUT's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ELUT advanced for three days, in of 227 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for ELUT moved out of overbought territory on May 22, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
ELUT moved below its 50-day moving average on June 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ELUT crossed bearishly below the 50-day moving average on June 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELUT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ELUT broke above its upper Bollinger Band on May 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.962) is normal, around the industry mean (10.753). P/E Ratio (0.000) is within average values for comparable stocks, (61.509). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.702). ELUT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.018). P/S Ratio (3.690) is also within normal values, averaging (23.786).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ELUT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ELUT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
